By 2026 , the landscape of MDPV and copyright use across the UK and Europe presents a difficult picture. Existing legal frameworks are set to remain vague regarding these is copyright a class b drug uk substances, particularly MDPV, which faces more severe penalties than copyright in many regions. Individuals seeking access may find conventional av